Executive summary

Persistent pain is common. Whereas acute pain may only impact
by interrupting current activity, episodic and persistent pain is likely to interfere with one or more aspects of a person's life and to affect his or her sense of identity. 1.2. There is clinical evidence from randomised controlled trials (RCTs) to support the use of SCS for pain from failed back surgical syndrome (FBSS), complex regional pain syndrome (CRPS), neuropathic pain, and ischaemic pain. The National Institute for Clinical Excellence (NICE) published guidance on SCS for chronic pain of neuropathic or ischaemic origin in 2008 (ref -TA 159). It recommended SCS for severe, prolonged pain responsive to a trial of stimulation in FBSS, CRPS, and neuropathic pain. NICE concluded that there was insufficient evidence of cost-effectiveness to recommend the use of SCS outside of controlled trials in ischaemic pain. We concur that further high-quality research on the use of SCS for chronic pain of ischaemic origin is required. Spinal cord stimulation (SCS) is an accepted method of pain control. SCS has been used for many years and is supported by a substantial evidence base. A multidisciplinary consensus group has been convened to create a guideline for the implementation and execution of an SCS programme for South Africa (SA). This article discusses the evidence and appropriate context of SCS delivery, and makes recommendations for patient selection and appropriate use. The consensus group has also described the possible complications following SCS. This guideline includes a literature review and a summary of controlled clinical trials of SCS.
The group notes that, in SA, SCS is performed mainly for painful neuropathies, failed back surgery, and chronic regional pain syndrome. It was noted that SCS is used to treat other conditions such as angina pectoris and ischaemic conditions, which have therefore been included in this guideline. These recommendations give guidance to practitioners delivering this treatment, to those who may wish to refer patients for SCS, and to those who care for patients with stimulators in situ. The recommendations also provide a resource for organisations that fund SCS. This guideline has drawn on the guidelines recently published by the British Pain Society, and parts of which have been reproduced with the society's permission.
These recommendations have been produced by a consensus group of relevant healthcare professionals. Opinion from outside the consensus group has been incorporated through consultation with representatives of all groups for whom these recommendations have relevance. The recommendations refer to the current body of evidence relating to SCS. The consensus group wishes to acknowledge and thank the task team of the British Pain Society for their help and input into this document. 
Scientific rationale
3.1. The use of stimulation techniques in modern pain medicine dates from the publication of the gate theory of Melzack and Wall in 1965, which described how stimulating neural pathways carrying innocuous (non-painful) information could influence the onward transmission of noxious information in the nervous system. 3.2. Although the introduction of SCS was inspired by the gate theory, its mechanism of action involves more than a direct inhibition of pain transmission in the dorsal horn of the spinal cord. If this were the principal mode of action, then SCS would control nociceptive pain, and this is not generally the case. Pain modulation by SCS also involves supra-spinal activity via the posterior columns of the spinal cord, probably recruiting endogenous inhibitory pathways. There is also a pronounced autonomic effect, though the mechanisms of this are not fully understood. 3.3. The preservation of topographically appropriate posterior column function seems to be necessary for SCS to be effective, but there is debate regarding which elements are necessary and to what degree.
Evidence
RCTs of SCS have been undertaken for FBSS, complex CRPS type 1, RAP, and chronic critical limb ischaemia (CLI)
. A summary of these RCTs and their findings is listed in Appendix 2. In addition to RCT evidence, systematic reviews of SCS have included case series and observational comparisons, particularly for FBSS and CRPS (see Appendix 2). It should be noted that present funding models in SA include only FBSS, CRPS, and some peripheral neuropathies including post-herpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN). These guidelines do include some data on the other described pathologies but shall be more focused on the former conditions.
• RCTs demonstrate that SCS is more effective for radicular (limb) pain following spinal surgery than either reoperation or management by nonsurgical therapy. 4.2. NICE published guidance on SCS for chronic pain of neuropathic or ischaemic origin in 2008 (ref -TA 159). With provisos regarding the severity and duration of pain and a trial of stimulation after multidisciplinary assessment, SCS is recommended as a treatment option for adults with chronic pain of neuropathic origin. This recommendation was based on RCT data and robust cost-effectiveness analyses for trials in FBSS and CRPS. The recommendation was extended to include all causes of chronic pain of neuropathic origin on the advice of nominated specialists. SCS is not, however, recommended for chronic pain of ischaemic origin, except in the context of research as part of a clinical trial. 4.3. NICE felt unable to recommend SCS for chronic pain of ischaemic origin for two reasons: lack of high-quality RCT data, and insufficient data to support robust economic modelling. Functional outcomes were considered in addition to improvements in pain levels. 4.4. In the case of CLI, NICE acknowledged that non-randomised evidence suggests there may be functional benefit for certain sub-groups of people. The evidence for improvement in healthrelated quality of life was not robust, and it was not possible to perform a cost-effectiveness analysis. 4.5. With regard to RAP, NICE assessed that the available data did not allow accurate identification of the population to be treated, or the available comparator treatments. The committee accepted that SCS was as effective as comparator treatments in the included studies. Again, no cost-effectiveness analysis was possible. 4.6. We concur with NICE that further high-quality research on the use of SCS in chronic pain of ischaemic origin is required.
SCS: Appropriate context for delivery
5.1. Pain interferes with physical function and is often associated with psychological problems. All patients being considered for SCS must be assessed with regard to physical, psychological, and social functioning. 5.2. An important approach to the treatment of pain is to attempt to modulate the unpleasant sensory experience by reducing the intensity, duration and frequency with which pain is felt. Medication, nerve blocks, physical therapies and SCS are all strategies used to achieve this outcome. SCS should not be considered as a first line of therapy, and other non-invasive options for treating the pain should be considered first. 5.3. Psychological interventions -mainly cognitive-behavioural therapy (CBT) -are largely focused on mitigating the interference in function that persistent pain induces. Such treatments may be offered in conjunction with SCS. 5.4. Qualitative psychological testing does not predict outcome, but assessment by a psychologist is desirable to assess the patient's beliefs, expectations, and understanding of the treatment in relation to the condition. 5.5. A multidisciplinary pain-management team is the most appropriate context in which to provide SCS. Such a team should be able to deliver a range of therapies for pain. Rechargeable batteries with increased longevity are now available. 8.9. Centres offering SCS to patients should ensure that the service is appropriately funded to support ongoing system maintenance, including the need for IPG replacement in those patients who do not have a rechargeable system in situ, and the possible need for lead or system revision. Patients must be made aware of all matters relating to funding prior to any SCS procedure.
The procedure 9.1 Preoperative assessment and preparation
9.1.1. Patients must be investigated appropriately to determine their fitness to undergo surgery and anaesthesia or sedation. 9.1.2. The most common organism to infect SCS systems is S. aureus. 9.1.3. The patient and operator should agree preoperatively on the proposed position of the IPG. 9.1.4. There is little published evidence regarding the use of antibiotic prophylaxis for SCS. Infection of an SCS system can be a significant problem and therefore its consequences justify the use of antibiotic prophylaxis. Antibiotics should be given as a single intravenous dose prior to starting the procedure. Appropriate cover for S. aureus should be ensured.
The theatre environment
9.2.1. Standard operating and post-anaesthesia care facilities must be available. 9.2.2. The operating theatre must be suitable for implant work. A laminar flow environment is suggested. 9.2.3. X-ray screening is mandatory for percutaneous lead placement. 9.2.4. A practitioner skilled in programming and trialing SCS must be present for the percutaneous procedures.
Table 2. Medical contraindications to the use of SCS
• Uncontrolled bleeding disorder; ongoing anticoagulant therapy is a relative contraindication
• Systemic or local sepsis
• Presence of a demand pacemaker or implanted defibrillator (relative contraindication)
• Immune suppression (relative contraindication) Table 3 . Surgical insertion of electrodes: Special considerations
• General contraindications to surgery should apply, such as coagulopathy or sepsis
• Surgical electrode systems are larger than percutaneous systems; to avoid the risk of cord compression, special note must be taken of the possibility of spinal canal stenosis if the electrodes are to be inserted beneath intact/residual laminae. Pre-operative MRI of the target area of the spine should be considered (if not already performed)
• Extensive laminectomy (particularly in the cervical spine) has potential morbidity. The appropriateness of further laminectomy to insert electrodes must be considered carefully when patients have previously undergone extensive laminectomy in or adjacent to the target area 9.3 Post-anaesthesia care and ward management 9.3.1. Programming the SCS should not begin until the patient is fully conscious. 9.3.2. Ward staff should be familiar with the aims and procedure of SCS, the condition that it is being used to manage, and the potential complications that may arise. 9.3.3. The post-operative observation regimen should consider potential complications such as spinal cord compression, neurological injury, bleeding, and infection. 9.3.4. Ward staff should be able to seek advice from a member of the implant team at any time.
Discharge and ongoing care
9.4.1. Adequate arrangements must be made for the implant team to conduct surveillance and follow-up; the patient should be able to contact an appropriate and experienced professional at any time. 9.4.2. Referring physicians must be given advice about all patients who are sent home after SCS implant. 9.4.3. In the event of complications related to the SCS or other pathology, there should be established relationships with other relevant disciplines such as spinal surgery and neurosurgery, microbiology and neuroradiology. 9.4.4. SCS is a long-term treatment for a chronic condition. Patients with non-rechargeable systems will need IPG replacement at some stage. Mechanisms should be in place to predict when this is likely to occur, so that, with planning, SCS function can be restored promptly. 9.4.5. If patients move beyond a reasonable travelling distance from the implanting centre, systems must be in place to transfer their care appropriately to other physicians.
Special precautions
10.1. Unipolar diathermy should be avoided in patients with SCS in situ. If its use is unavoidable, the reference plate should be positioned so that the SCS components are outside the electrical field of the diathermy. 10.2. The interaction of MRI and SCS is complex. The magnetic field may cause leads to move, resulting in loss of effect or neural damage, or heat the implant components, resulting in discomfort, tissue damage, or software malfunction. In addition, the location of the leads in relation to the site of imaging interest may corrupt the image. Patients with SCS in situ who need investigation with MRI may pose specific problems that should be discussed with an experienced neuro-radiologist. If there is any doubt about the compatibility, then alternative imaging (such as computed tomography (CT) scan or myelography) should be performed. It has been established that if MRI studies are unavoidable, then the IPG should be switched off during the scans and thereafter checked for programming errors. 10.3. The presence of a cardiac pacemaker is a relative contraindication to SCS. Most contemporary pacemakers are operated in the demand mode -they monitor intrinsic cardiac activity, and may be inhibited by spontaneous extra-cardiac electrical activity. They may sense extraneous electrical activity from SCS devices and misinterpret it as appropriate cardiac activity. The pacemaker may then either respond by inhibiting pacing or by reverting to an asynchronous pacing mode. Inhibition of pacing can be potentially dangerous for the patient; asynchronous pacing is less serious, but still compromises pacemaker function. In such circumstances, it has been suggested that bipolar pacemaker sensing should be employed, as it is inherently less sensitive to extraneous signals than the unipolar pacing mode. 
Complications of SCS
11.1. SCS has been used in many thousands of patients worldwide; some clinical centres have reported follow-up of >10 years. Major complications of SCS are rare, but minor ones are common. Most problems are technical, with the most common complication being lead migration. These complications should be discussed during the consent process. 11.2. Neurological damage relating to epidural electrode placement is a rare complication and may occur with both percutaneous and surgical electrodes. Damage may occur directly or from epidural haematoma or infection. These latter complications are reversible if diagnosed and treated promptly, emphasising the importance of postoperative neurological observations by experienced staff. Vigilance and access to early imaging are essential (see 10.2). 11.3. Dural puncture may occur during percutaneous insertion of electrodes. This happens most frequently with the Tuohy needle, but may occur with the guide wire or the stimulating electrode. 11.4. Infection of implanted neurostimulators is a serious problem and must never be ignored. Usually, the infection will not resolve unless the whole SCS system is explanted. Infection of the entire system is rare but can result in epidural abscess with potentially disastrous neurological consequences. In such cases explantation is required. 11.5. Patients should be aware that not only will surgery be necessary to replace a depleted IPG but that it may also be necessary to revise the electrodes or connections. 11.6. Electrode migration (see 11.1) may occur immediately following the procedure, at any time during the trial period or following IPG insertion. Cervical electrodes are more likely to be dislodged than those in the thoracic region. Migration is less likely with surgical electrodes. Recent improvements in anchor designs have been shown to reduce migration. 11.7. Other potential problems include fluid entering the connectors or electrode, lead breakage, and disconnection.
Patient information
12.1. The risks and limitations of SCS should be discussed with patients, who should be given written information in a form that they can understand. 12.2. Patients must be aware of the evidence for the efficacy of SCS for the indication in their case. 12.3. Patients should be given information relating to complications and outcomes. 12.4. Detailed information regarding the procedure of SCS insertion, including the operating theatre environment, is necessary. 12.5. Patients should understand that SCS provides benefit only as part of a multidimensional approach to symptom management. 12.6. Patients should understand the need for ongoing care following SCS, including the likelihood of needing further surgery.
Results
Search method
RCTs and systematic reviews were identified from searches of MEDLINE (PubMed) + Improvements in outcome in SCS group v. comparator group at follow up (p≤0.05).
-Decrement in outcome in SCS group v. comparator group at follow up (p≤0.05).
= Difference in outcome between SCS group v. comparator group at follow up (p>0.05).
